Skip to content
TirzepatideReport

Tirzepatide monograph · Evidence review

HealthRX Tirzepatide Review: Cost, Oral Tablet & Honest Verdict (2026)

An honest 2026 review of HealthRX tirzepatide — LegitScript-certified, a rare oral tablet, 503A compounding, company-stated pricing, and the catches.

Researched & written by Alan Pierce · last updated

Clinical Pharmacology Writer

On this page

Editorial pick

CoreAge Rx

$149/mo flat

Doctor-reviewed tirzepatide with one flat price and built-in human support.

Advertising disclosure · we may earn a commission at no extra cost to you.

Check availability
vs median
$130/mo below the $279 median
Market
$109–$429/mo across 388 providers
Dispensed
Compounded tirzepatide (503A)

Popular alternative

Found

Established, physician-designed weight care with a broad formulary — real brand-name Zepbound/Mounjaro alongside compounded tirzepatide, paired with coaching.

$289/mo m2m ($169/mo on 12-mo prepay)

Check Found availability

HealthRX is a LegitScript-certified (#50087439), physician-supervised telehealth for medical weight loss that is unusual in offering a rare oral GLP tablet alongside the standard injectable, filled by a licensed U.S. 503A pharmacy. This review covers what HealthRX is, what it dispenses, the compounded-versus-brand distinction, its pricing, and the catches. Every fact here comes from the company's own published program.

What HealthRX is

HealthRX is a physician-supervised telehealth for medical weight loss that is LegitScript-certified (#50087439) — a genuine third-party trust signal most compounded startups lack. A U.S. board-certified physician reviews an online intake and, where appropriate, compounded tirzepatide (and semaglutide) is filled by a licensed U.S. 503A pharmacy with transparent monthly pricing and no insurance required. HealthRX is unusual in offering an oral GLP tablet in addition to the standard injectable.

The compounded-vs-brand question

Two very different products share the name tirzepatide:

  • Brand tirzepatide is Eli Lilly's FDA-approved Zepbound (weight management, obstructive sleep apnea) and Mounjaro (type 2 diabetes) — the exact molecule and dose studied in the pivotal trials.
  • Compounded tirzepatide is pharmacy-made, not FDA-approved, and was not the product tested in those trials.

HealthRX's main tirzepatide offerings are compounded (through a 503A pharmacy), with a brand pass-through option quoted separately at a much higher price. That distinction matters more in 2026: the FDA declared the tirzepatide shortage resolved in October 2024, and the enforcement discretion that permitted routine large-scale compounding ended in early 2025 (around February 18, 2025 for 503A pharmacies, March 19, 2025 for 503B outsourcing facilities) — the full timeline is in our guide to whether compounded tirzepatide is still legal in 2026. The oral GLP tablet in particular lacks the injectable's robust absorption and efficacy evidence.

§ HealthRX — Company-Stated Tiers

TierHealthRX priceNote
Compounded GLP injectable~$189/monthCompounded, not FDA-approved
Oral GLP tablet~$239/monthThinner absorption/efficacy evidence
GLP + GIP option~$349/monthCompany-stated
Brand pass-through~$1,299Above LillyDirect self-pay
HealthRX tiers are largely company-stated and were not all independently verified on a live public price page. Compounded options are not FDA-approved; the oral tablet has a thinner evidence base. The ~$1,299 brand pass-through is well above brand Zepbound via LillyDirect (~$299–$449/month; vials, in effect since December 1, 2025).

What HealthRX costs in 2026

Company-stated tiers run about $189/month for the compounded GLP injectable, ~$239/month for the oral tablet, and ~$349/month for a GLP+GIP option, with a brand pass-through option quoted around $1,299. Pricing is described as transparent with no insurance required. The honest caveat is that several of these tiers are stated by the company rather than confirmed on a live public price page during our review, and the number of states served is not published — so verify the price and availability in your state directly.

For context, LillyDirect sells brand Zepbound self-pay vials at roughly $299–$449/month depending on dose (prices in effect since December 1, 2025; 28-day supply) — well below HealthRX's ~$1,299 brand pass-through, so if you want the brand drug, LillyDirect is likely the cheaper route. For the full cash-price picture, see our Zepbound cost and savings guide.

How the care model holds up

HealthRX's strengths are its LegitScript certification (#50087439) — a real trust signal — physician supervision with a licensed U.S. 503A compounding pharmacy, a rare oral GLP tablet alongside injectable, and transparent monthly pricing with no insurance required. The trade-offs: the main tirzepatide is compounded and not FDA-approved; several tiers are company-stated and could not be independently verified on a live page; the brand tier is an expensive pass-through (~$1,299) — far above LillyDirect; and the number of states served is not published. Tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-11, and better than semaglutide head-to-head2 — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

The honest verdict

HealthRX is a reasonable pick if you value a LegitScript-certified, physician-supervised program with a 503A pharmacy and want a rare oral GLP tablet option — and you are comfortable with a compounded, non-FDA-approved product. The LegitScript certification is a genuine plus. The reservations are that several tiers are company-stated and unverified, the brand pass-through (~$1,299) is far above LillyDirect, and the states served are not published. If you want the brand drug, LillyDirect is likely cheaper; if you want a flat, verifiable compounded price with included support, weigh CoreAge Rx. See our best tirzepatide providers ranking and best place to get Zepbound online roundup.

Frequently asked questions

How much does tirzepatide cost through HealthRX?

Company-stated tiers run about $189/month for the compounded GLP injectable, ~$239/month for the oral tablet, and ~$349/month for a GLP+GIP option, with a brand pass-through option quoted around $1,299. Several of these are stated by the company rather than confirmed on a live public price page, so verify directly. As a benchmark, brand Zepbound self-pay vials run roughly $299–$449/month via LillyDirect (in effect since December 1, 2025) — well below the ~$1,299 pass-through.

Is HealthRX tirzepatide compounded or brand?

Its main tirzepatide offerings are compounded, filled by a licensed U.S. 503A pharmacy, with a separate, much more expensive brand pass-through option (~$1,299). Compounded tirzepatide is not FDA-approved and was not studied in the pivotal trials, and the oral GLP tablet in particular has a thinner evidence base. After the FDA declared the shortage resolved in late 2024, large-scale compounding was restricted in early 2025.

Is HealthRX legit?

HealthRX is LegitScript-certified (#50087439) and physician-supervised, with a licensed U.S. 503A compounding pharmacy — the LegitScript certification is a genuine third-party trust signal most compounded providers lack. The caveats are that several pricing tiers are company-stated and could not be independently verified on a live page, the brand tier is an expensive pass-through (~$1,299), and the number of states served is not published.

Is the HealthRX oral tablet as effective as the injection?

It cannot be assumed to be. Tirzepatide's trial-grade efficacy — about 15–21% average weight loss over 72 weeks in SURMOUNT-1, and beating semaglutide in SURMOUNT-5 — was established with the brand injectable molecule. Oral GLP tablets were not tested in those trials and generally have weaker absorption and efficacy evidence, so treat the oral option with particular caution and discuss expectations with the prescriber.

References(2)

  1. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, and the SURMOUNT-1 Investigators (2022). Tirzepatide Once Weekly for the Treatment of Obesity.. New England Journal of Medicine. PMID: 35658024. https://pubmed.ncbi.nlm.nih.gov/35658024/
  2. Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Bays HE, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5).. New England Journal of Medicine. PMID: 40353578. https://pubmed.ncbi.nlm.nih.gov/40353578/

About the author

Alan Pierce

Clinical Pharmacology Writer

About Tirzepatide Report · How we verify prices · This page last updated August 2026

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.